Urogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC Wainwright

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright's target price points to a potential upside of 270.64% from the company's previous close.

URGN has been the topic of several other reports. Guggenheim reaffirmed a "buy" rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a research report on Monday. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Finally, Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.86.

Urogen Pharma Stock Down 0.7%

Shares of NASDAQ URGN opened at $13.49 on Tuesday. The business's 50 day moving average is $9.72 and its two-hundred day moving average is $10.26. The company has a market cap of $622.02 million, a P/E ratio of -4.24 and a beta of 1.02. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $18.15.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. Sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the transaction, the insider owned 153,378 shares of the company's stock, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of URGN. RA Capital Management L.P. acquired a new position in Urogen Pharma in the first quarter worth $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after acquiring an additional 2,983,368 shares during the period. Toronto Dominion Bank acquired a new position in shares of Urogen Pharma during the fourth quarter valued at $18,628,000. Acorn Capital Advisors LLC acquired a new position in shares of Urogen Pharma during the fourth quarter valued at $16,149,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Urogen Pharma during the fourth quarter valued at $14,608,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.